Overcoming Immune Evasion in Melanoma
Melanoma is the most aggressive and dangerous form of skin cancer that develops from transformed melanocytes. It is crucial to identify melanoma at its early stages, in situ, as it is “curable” at this stage. However, after metastasis, it is difficult to treat and the five-year survival is only 25%....
Main Authors: | Kevinn Eddy, Suzie Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/23/8984 |
Similar Items
-
Enhanced Systemic Antitumour Immunity by Hypofractionated Radiotherapy and Anti-PD-L1 Therapy in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
by: Tatsuya Deguchi, et al.
Published: (2023-06-01) -
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
by: Bruna Pereira Sorroche, et al.
Published: (2023-03-01) -
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
by: Jan-Malte Placke, et al.
Published: (2021-09-01) -
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
by: Paolo A. Ascierto, et al.
Published: (2017-08-01) -
An immune risk score predicts progression-free survival of melanoma patients in South China receiving anti-PD-1 inhibitor therapy—a retrospective cohort study examining 66 circulating immune cell subsets
by: Peidong Chi, et al.
Published: (2022-12-01)